This content is machine translated Acute lymphoblastic leukemia Addition of blinatumomab to chemotherapy improves survival in children Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. Children with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL) with standard risk (SR) have a high survival rate when treated...…
View Post 8 min This content is machine translated Hematology From anemia to blood cancer – the latest findings at a glance Hematology covers a broad spectrum of indications with very heterogeneous disease patterns. Accordingly, intensive research is being carried out to provide patients with effective treatment. Rarer diseases are examined just…
View Post 6 min This content is machine translated CAR-T Cells Own immune cell as therapy With the rapid development of new therapeutic options in oncology, immunotherapy has a high priority. Thus, CAR T cells are also a promising approach to treat advanced cancers. In particular,…
View Post 3 min This content is machine translated Cancer medicine of the future Car-T cell therapy and its application in practice CAR-T cell technology is considered the latest achievement in cancer medicine. The first approvals in Europe took place in mid-2018 – Switzerland followed at the end of 2018. Currently, the…
View Post 3 min This content is machine translated Immunotherapy Wider use for CAR-T cell treatment possible in the future? CAR-T cells have solved a central problem in cancer therapy – they make tumors visible again to the immune system. The initial successes in B-cell lymphomas are now attracting a…
View Post 10 min This content is machine translated Developments in the field of acute leukemias The beginning of a new era in therapy Therapy for AML and ALL is on the move. In the future, it will be much more differentiated. Some new options have already been approved, while others are in development…
View Post 4 min This content is machine translated DKK in Berlin - Leukemia treatment Revolution through personalized therapy Knowledge of molecular markers in leukemias could help identify high-risk patients in the future. In addition, there is an opportunity to develop further targeted therapeutic approaches. Some already approved therapeutics…
View Post 9 min This content is machine translated Acute lymphoblastic leukemias in children and adolescents Progress through better risk stratification Acute lymphoblastic leukemia is the most common childhood cancer. It is treated in a risk-adapted manner and is curable in the majority of cases. New innovative drugs such as immunotherapies…
View Post 4 min This content is machine translated Childhood cancer Progress made in recent years does not reach everyone Early death after childhood cancer diagnosis remains a challenge. Infants, ethnic minorities, and the socioeconomically worse off are at higher risk for early death. The reasons for this need to…
View Post 4 min This content is machine translated Breast cancer/lung cancer/leukemia Targeted Therapy At the beginning of August, a press roundtable on the specialist field of oncology was held in Zurich. Insight was provided into “targeted therapy” in breast carcinoma, acute lymphoblastic leukemia…
View Post 7 min This content is machine translated 57th ASH Meeting in Orlando New field of application for rituximab The ASH Congress was held last year in Orlando. This time, one of the topics was the efficacy of rituximab in adult patients with B-precursor acute lymphoblastic leukemia (ALL). Up…
